GIC 201
Alternative Names: GIC-201Latest Information Update: 15 Sep 2022
At a glance
- Originator GICELL
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 06 Sep 2022 Preclinical trials in Solid tumours in South Korea (Parenteral) Before September 2022